BR112014018815A2 - - Google Patents

Info

Publication number
BR112014018815A2
BR112014018815A2 BR112014018815A BR112014018815A BR112014018815A2 BR 112014018815 A2 BR112014018815 A2 BR 112014018815A2 BR 112014018815 A BR112014018815 A BR 112014018815A BR 112014018815 A BR112014018815 A BR 112014018815A BR 112014018815 A2 BR112014018815 A2 BR 112014018815A2
Authority
BR
Brazil
Application number
BR112014018815A
Other languages
Portuguese (pt)
Other versions
BR112014018815B1 (pt
BR112014018815A8 (pt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of BR112014018815A2 publication Critical patent/BR112014018815A2/pt
Publication of BR112014018815A8 publication Critical patent/BR112014018815A8/pt
Publication of BR112014018815B1 publication Critical patent/BR112014018815B1/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/095Neisseria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6037Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/62Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
BR112014018815-7A 2012-01-30 2013-01-29 Composição imunogênica compreendendo conjugado proteína-polissacarídeo x de n. meningitidis BR112014018815B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN281MU2012 2012-01-30
IN281/MUM/2012 2012-01-30
PCT/IB2013/050739 WO2013114268A1 (en) 2012-01-30 2013-01-29 Immunogenic composition

Publications (3)

Publication Number Publication Date
BR112014018815A2 true BR112014018815A2 (enExample) 2017-06-20
BR112014018815A8 BR112014018815A8 (pt) 2017-07-11
BR112014018815B1 BR112014018815B1 (pt) 2022-07-12

Family

ID=54259032

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014018815-7A BR112014018815B1 (pt) 2012-01-30 2013-01-29 Composição imunogênica compreendendo conjugado proteína-polissacarídeo x de n. meningitidis

Country Status (17)

Country Link
US (1) US9198977B2 (enExample)
EP (1) EP2809349B1 (enExample)
JP (1) JP6042455B2 (enExample)
KR (1) KR101897317B1 (enExample)
CN (1) CN104302315B (enExample)
BR (1) BR112014018815B1 (enExample)
CA (1) CA2863178C (enExample)
DK (1) DK2809349T3 (enExample)
ES (1) ES2707294T3 (enExample)
HU (1) HUE040914T4 (enExample)
MX (1) MX354103B (enExample)
PT (1) PT2809349T (enExample)
RU (1) RU2634405C2 (enExample)
SG (1) SG11201404447WA (enExample)
SI (1) SI2809349T1 (enExample)
TR (1) TR201900778T4 (enExample)
WO (1) WO2013114268A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130122810A (ko) 2005-06-27 2013-11-08 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신 제조 방법
MX364644B (es) * 2012-11-21 2019-05-03 Serum Inst India Ltd Produccion de altos rendimientos de polisacaridos bacteriales.
MX365726B (es) * 2013-08-24 2019-06-11 Bharat Biotech Int Ltd Vacuna bacteriana y metodos para la fabricacion de la misma.
EP2921856B1 (en) 2014-03-18 2016-09-14 Serum Institute Of India Private Limited A quantitative assay for 4-pyrrolidinopyridine (4-ppy) in polysaccharide-protein conjugate vaccines
PE20180460A1 (es) * 2015-06-08 2018-03-06 Serum Inst Of India Private Ltd Metodos para mejorar la adsorcion de conjugados de polisacarido-proteina y una formulacion de vacuna multivalente obtenida con los mismos
AU2016290233A1 (en) * 2015-07-04 2018-01-25 Bharat Biotech International Limited Polysaccharide vaccine formulations and processes for industrial production of bacterial polysaccharides
MX2018010920A (es) * 2016-03-15 2019-03-06 Msd Wellcome Trust Hilleman Laboratories Pvt Ltd Nuevos conjugados de polisacarido-proteina, y procedimiento para obtener los mismos.
CN106110316A (zh) * 2016-06-27 2016-11-16 北京智飞绿竹生物制药有限公司 一种肺炎球菌结合物组合疫苗的制备方法
LT3506935T (lt) 2016-09-02 2024-04-25 Sanofi Pasteur, Inc. Vakcina nuo neisseria meningitidis
CN106397537B (zh) * 2016-10-13 2020-01-07 李红臣 一种高效快速的多糖蛋白结合疫苗纯化分析方法
CA3062399A1 (en) 2017-05-05 2018-11-08 Serum Institute Of India Private Limited Method for removal of impurities from bacterial capsular polysaccharide based preparations
BR112019027182A2 (pt) * 2017-06-27 2020-06-30 Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. nova composição de vacina conjugada de proteína - polissacarídeo multivalente e formulação da mesma
WO2019145981A1 (en) * 2018-01-29 2019-08-01 Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. Novel meningococcal vaccine composition and process thereof
WO2019198096A1 (en) * 2018-04-11 2019-10-17 Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. Tetravalent meningococcal vaccine composition and process to prepare thereof
JOP20200214A1 (ar) 2019-09-03 2021-03-03 Serum Institute Of India Pvt Ltd تركيبات مولدة للمناعة ضد الأمراض المعوية وطرق لتحضيرها
MX2022003682A (es) 2019-09-27 2022-04-25 Pfizer Composiciones de neisseria meningitidis y metodos de las mismas.
US12053515B2 (en) 2020-08-10 2024-08-06 Inventprise, Inc. Multivalent pneumococcal glycoconjugate vaccines containing emerging serotype 24F
CN118078981A (zh) * 2024-04-26 2024-05-28 成都康华生物制品股份有限公司 一种基于双蛋白载体的五价脑膜炎球菌多糖结合疫苗的制备方法及其产品

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2763244B1 (fr) * 1997-05-14 2003-08-01 Pasteur Merieux Serums Vacc Composition vaccinale multivalente a porteur mixte
HU227893B1 (en) * 2000-06-29 2012-05-29 Glaxosmithkline Biolog Sa Vaccine compositions
GB0115176D0 (en) * 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
GB0130215D0 (en) * 2001-12-18 2002-02-06 Glaxosmithkline Biolog Sa Vaccine
EP1961426B1 (en) * 2003-10-02 2011-04-27 Novartis Vaccines and Diagnostics S.r.l. Combined meningitis vaccines
GB0513069D0 (en) * 2005-06-27 2005-08-03 Glaxosmithkline Biolog Sa Immunogenic composition
KR20130122810A (ko) * 2005-06-27 2013-11-08 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신 제조 방법
BRPI0615420A2 (pt) * 2005-09-01 2011-05-17 Novartis Vaccines & Diagnostic vacinação múltipla que inclui meningococo do sorogrupo c
DK2384765T3 (en) * 2005-12-22 2017-01-09 Glaxosmithkline Biologicals Sa Vaccine against Streptococcus pneumoniae.
GB0703369D0 (en) * 2007-02-21 2007-03-28 Health Prot Agency Compositions Comprising Capsular Polysaccharides and Their Use as Vaccines
SG181750A1 (en) * 2009-12-17 2012-07-30 Fina Biosolutions Llc Chemical reagents for the activation of polysaccharides in the preparation of conjugate vaccines
ES2820898T3 (es) * 2012-05-22 2021-04-22 Glaxosmithkline Biologicals Sa Conjugado del serogrupo X de meningococos

Also Published As

Publication number Publication date
MX2014009250A (es) 2015-03-19
CN104302315A (zh) 2015-01-21
US20140377302A1 (en) 2014-12-25
US9198977B2 (en) 2015-12-01
SG11201404447WA (en) 2014-08-28
DK2809349T3 (da) 2019-02-18
ES2707294T3 (es) 2019-04-03
EP2809349A1 (en) 2014-12-10
CN104302315B (zh) 2018-02-06
JP2015509111A (ja) 2015-03-26
RU2634405C2 (ru) 2017-10-26
WO2013114268A1 (en) 2013-08-08
BR112014018815B1 (pt) 2022-07-12
EP2809349B1 (en) 2018-12-19
PT2809349T (pt) 2019-02-01
RU2014134288A (ru) 2016-03-20
CA2863178C (en) 2021-04-06
KR101897317B1 (ko) 2018-09-11
TR201900778T4 (tr) 2019-02-21
JP6042455B2 (ja) 2016-12-14
EP2809349A4 (en) 2015-08-26
KR20140123553A (ko) 2014-10-22
BR112014018815A8 (pt) 2017-07-11
HUE040914T4 (hu) 2019-05-28
SI2809349T1 (sl) 2019-03-29
MX354103B (es) 2018-02-13
CA2863178A1 (en) 2013-08-08

Similar Documents

Publication Publication Date Title
BR112014017635A2 (enExample)
BR112014017614A2 (enExample)
BR112014025621A2 (enExample)
BR112014017625A2 (enExample)
BR112014019323A2 (enExample)
BR112014017659A2 (enExample)
BR112014019875A2 (enExample)
BR112014017646A2 (enExample)
BR112014017607A2 (enExample)
BR112014017638A2 (enExample)
BR112014017634A2 (enExample)
BR112014017644A2 (enExample)
BR112014018815A2 (enExample)
BR112014017588A2 (enExample)
BR112014017618A2 (enExample)
BR112014017647A2 (enExample)
BR112014018671A2 (enExample)
BR112014017623A2 (enExample)
BR112014017652A2 (enExample)
BR112014017630A2 (enExample)
BR112014017627A2 (enExample)
BR112014017621A2 (enExample)
BR112014017631A2 (enExample)
BR112014017641A2 (enExample)
BR112014017622A2 (enExample)

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 29/01/2013, OBSERVADAS AS CONDICOES LEGAIS